Sun Pharma's Q4 performance had the 'Taro effect' written all over it. Sun completed the much-litigated Taro acquisition in September 2010 rendering its consolidated quarterly performance incomparable with the same quarter last fiscal.

 

However, Taro has registered strong growth in sales and improvement in margins on a sequential basis indicating positive impact of Sun's management on its operations.

 

It contributed one-third of Sun's consolidated net sales and one-fourth to the latter's net profit. As a result, Sun managed to post 35% rise in net sales and 12% growth in net profit - exceeding analysts' expectations.

Comments

Search RSS

All rights reserved."